Based on analysis of employer experiences, vendor data, and expert interviews, PHTI outlines five key recommendations for employers: Establish clear, clinically driven eligibility pathways for GLP-1 coverage Require participation in behavior, nutrition, or lifestyle change programs as a condition of coverage Provide structured support for employees who choose to taper or discontinue GLP-1 therapy Review existing vendor capabilities before adding additional point solutions Contract with vendors to drive outcomes while examining overall program costs The report identifies three critical phases where these solutions can support employers in managing their GLP-1 coverage: Initiation: Providing targeted GLP-1 coverage using clinical criteria, behavioral or AI-based screening, narrow prescribing networks, or step-therapy pathways that include lower-cost alternatives or lifestyle change programs

This central mechanism has prompted researchers to investigate whether tirzepatide might influence other reward-driven behaviors, including substance use and addiction
If symptoms are severe or persistent, a medication review may be warranted to explore alternative diabetes therapies, though this decision should be made collaboratively based on individual circumstances and the balance of benefits and risks
Nutrient 2021;13(10):3325 4) Irune E, Dwivedi RC, Nutting CM, et al